Role of comorbidities like diabetes on severe acute respiratory syndrome coronavirus-2: A review
Data
2020Autor
Das, Subham
Anu, K.R.
Raosaheb Birangal, Sumit
Nitin Nikam, Ajinkya
Pandey, Abhijeet
Mutalik, Srinivas
Joseph, Alex
Metadata
Mostrar registro completo
Documentos PDF
Imagenes y Videos
Resumo
Pandemic coronavirus disease-2019, commonly known as COVID-19 caused by severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2) is a highly contagious disease with a
high mortality rate. Various comorbidities and their associated symptoms accompany SARSCoV-2 infection. Among the various comorbidities like hypertension, cardiovascular disease
and chronic obstructive pulmonary disease, diabetes considered as one of the critical
comorbidity, which could affect the survival of infected patients. The severity of COVID-19
disease intensifies in patients with elevated glucose level probably via amplified proinflammatory cytokine response, poor innate immunity and downregulated angiotensinconverting enzyme 2. Thus, the use of ACE inhibitors or angiotensin receptor blockers could
worsen the glucose level in patients suffering from novel coronavirus infection. It also
observed that the direct β-cell damage caused by virus, hypokalemia and cytokine and fetuinA mediated increase in insulin resistance could also deteriorate the diabetic condition in
COVID-19 patients. This review highlights the current scenario of coronavirus disease in preexisting diabetic patients, epidemiology, molecular perception, investigations, treatment and
management of COVID-19 disease in patients with pre-existing diabetes. Along with this, we
have also discussed unexplored therapies and future perspectives for coronavirus infection.
Palabras clave
Coronavirus; COVID-19; SARS-CoV-2; Diabetes; Comorbidities; Epidemiology; Treatment; ManagementLink para o recurso
https://doi.org/10.1016/j.lfs.2020.118202Collections
Estadísticas Google Analytics
Comments
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.